Eejit
The Freeman
- Joined
- May 19, 2004
- Messages
- 13,510
- Reaction score
- 219
It's about time the pharma multinationals learned the meaning of the word "ethics".
But it's not all good,
GSK will publish details of 13,500 chemical compounds from its own library that have potential to act against the parasite that causes malaria in sub-Saharan Africa, killing at least one million children every year.
It took a team of five investigators a year to screen the two million compounds in GSK's library – its entire collection of potential drugs and possibly the biggest such library in the world.
Witty's speech takes forward the agenda he set out nearly a year ago at Harvard University, when he pledged to put all the potential drugs for neglected diseases GSK holds in a "patent pool", waiving the company's intellectual property rights so that any scientists could investigate them. He also promised to cut the price of all GSK drugs in the world's poorest countries and to reinvest 20% of all profits it made there in projects to help local people.
But it's not all good,
[Witty] admitted he was disappointed other drug companies had not taken up the invitation he had held out to put their patents into the neglected diseases pool as well.
We need moar!Tido von Schoen-Angerer, director of Médecins sans Frontières' campaign for essential medicines, said: "The fact that they are opening up their compounds for malaria is a good step. It is something like we have been calling for for some years. It would be good if other companies would do the same thing, and for other diseases." But Oxfam, Médecins sans Frontières and other NGOs are still very critical of GSK's reluctance to wholeheartedly embrace a patent pool for HIV drugs that is being set up by Unitaid.